Vaxart (STU:NB11) FFO


STU:NB11 Vaxart Inc STU:NB11
59 GF Score
Price €0.60
GF Value €8.85
! 3 Warning Signs
View Full Analysis

What is Vaxart FFO?

FFO (Funds from operations) only applies to REITs.

STU:NB11
59GF Score
Vaxart Inc STU:NB11
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Vaxart (STU:NB11) Overvalued in 2026?

Based on GuruFocus' analysis, Vaxart stock appears to be undervalued. The current stock price of €0.60 is trading 93.2% below its estimated GF Value™ of €8.85.

Key valuation signals for STU:NB11:

  • FFO:
  • GF Value™: €8.85 vs. price of €0.60 (93.2% below fair value)
  • GF Score™: 59/100 with 3 warning signs

No single metric tells the full story. See the STU:NB11 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Vaxart Business Description

Other Exchanges VXRT:USA
Address 170 Harbor Way, Suite 300, South San Francisco, CA, USA, 94080
Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines based on its Vector Adjuvant Antigen Standardized Technology to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically, all the business activity functions through the region of the United States.
59GF Score

Get the complete analysis for STU:NB11

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.60
Price
€8.85
GF Value